FOLD - AMICUS THERAPEUTICS, INC.

QQQ $ 604.27 $ -5.89 (-0.96 %)

DIA $ 464.98 $ -3.44 (-0.73 %)

SPY $ 666.76 $ -3.49 (-0.52 %)

TLT $ 92.19 $ 0.06 (0.07 %)

GLD $ 376.01 $ 0.04 (0.01 %)

Previous Close

$ 8.55

Open

$ 8.48

Bid

$ 8.26 x 182

Ask

$ 8.87 x 2

Day's Range

$ 8.37 - $ 8.62

52 Week Range

$ 5.51 - $ 12.65

Volume

3,326,429

Average Volume

Market Cap

2.64B

Beta (5Y Monthly)

$ 0.78

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	07-31-2025	06-30-2025	10-Q
2	05-01-2025	03-31-2025	10-Q
3	02-19-2025	12-31-2024	10-K
4	11-06-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	02-28-2024	12-31-2023	10-K
8	11-08-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-10-2023	03-31-2023	10-Q
11	03-01-2023	12-31-2022	10-K
12	11-07-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-10-2022	03-31-2022	10-Q
15	02-24-2022	12-31-2021	10-K
16	11-09-2021	09-30-2021	10-Q
17	08-05-2021	06-30-2021	10-Q
18	05-10-2021	03-31-2021	10-Q
19	03-01-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-10-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-02-2020	12-31-2019	10-K
24	11-12-2019	09-30-2019	10-Q
25	08-08-2019	06-30-2019	10-Q
26	05-09-2019	03-31-2019	10-Q
27	02-28-2019	12-31-2018	10-K
28	11-05-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-09-2018	03-31-2018	10-Q
31	03-01-2018	12-31-2017	10-K
32	11-08-2017	09-30-2017	10-Q
33	08-07-2017	06-30-2017	10-Q
34	05-09-2017	03-31-2017	10-Q
35	03-01-2017	12-31-2016	10-K
36	11-07-2016	09-30-2016	10-Q
37	08-09-2016	06-30-2016	10-Q
38	05-03-2016	03-31-2016	10-Q
39	02-29-2016	12-31-2015	10-K
40	11-04-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-csx-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday

This CSX Analyst Turns Bullish; Here Are T...
09/18/2025 11:23:26

Needham Upgrades Amicus Therapeutics to Bu...
09/18/2025 10:00:55

Needham analyst Gil Blum upgrades Amicus Therapeutics (NASDAQ:FOLD) from Hold to Buy and announces $14 price target.

Amicus Therapeutics Reports 4-Year Muscle ...
09/08/2025 13:05:49

Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarke...

Amicus Therapeutics Affirms FY2025 Sales G...
07/31/2025 11:14:20

2025 Financial GuidanceAmicus reiterates its financial guidance for 2025, as follows:Total Revenue Growth115% to 22% Galafold R...

Amicus Therapeutics Q2 Adj. EPS $0.01 Beat...
07/31/2025 11:06:47

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $...

Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

Morgan Stanley Upgrades Amicus Therapeutic...
07/17/2025 11:33:37

Morgan Stanley analyst Jeffrey Hung upgrades Amicus Therapeutics (NASDAQ:FOLD) from Equal-Weight to Overweight and raises th...

Amicus Therapeutics Receives Approval From...
06/25/2025 11:05:29

Amicus Therapeutics Announced The Publicat...
06/03/2025 11:13:06

PROPEL was a 52-week, double-blind randomized global study designed to assess the efficacy, safety, and tolerability of cipaglu...

UBS Maintains Buy on Amicus Therapeutics, ...
05/02/2025 22:37:55

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $21 to $22.

Goldman Sachs Maintains Neutral on Amicus ...
05/02/2025 16:47:03

Goldman Sachs analyst Salveen Richter maintains Amicus Therapeutics (NASDAQ:FOLD) with a Neutral and lowers the price target...

12 Health Care Stocks Moving In Thursday's...
05/01/2025 12:05:58

Amicus Therapeutics Sees FY25 Revenue Grow...
05/01/2025 11:11:34

Amicus Therapeutics Q1 Adj. EPS $0.03 Beat...
05/01/2025 11:10:22

Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $...

Earnings Scheduled For May 1, 2025
05/01/2025 08:32:37

Reported Earlier, Dimerix And Amicus Thera...
05/01/2025 07:19:37

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) D...

Amicus Therapeutics Earnings Preview
04/30/2025 16:01:30

Wells Fargo Maintains Overweight on Amicus...
02/20/2025 13:35:34

Wells Fargo analyst Tiago Fauth maintains Amicus Therapeutics (NASDAQ:FOLD) with a Overweight and lowers the price target fr...

Needham Reiterates Hold on Amicus Therapeu...
02/20/2025 09:58:00

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:FOLD) from Hold to Hold.

Amicus Therapeutics 2025 Guidance: Expects...
02/19/2025 12:03:47

2025 Financial GuidanceTo advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for...